Introduction
Carbonic anhydrases (CAs) are metalloenzymes that catalyze the reversible hydration of CO 2 into bicarbonate and protons and thus are essential to maintaining intracellular Abstract Membrane-associated carbonic anhydrase (CA) isoform IV participates in carbon metabolism and pH homeostasis and is implicated in the development of eye diseases such as retinitis pigmentosa and glaucoma. A series of substituted benzenesulfonamides were designed and their binding affinity to CA IV was determined by fluorescent thermal shift assay and isothermal titration calorimetry (ITC). Compound [(4-chloro-2-phenylsulfanyl-5-sulfamoylbenzoyl)amino]propyl acetate (19) bound CA IV with the K d of 1.0 nM and exhibited significant selectivity over the remaining 11 human CA isoforms. The compound could be developed as a drug targeting CA IV. Various forms of recombinant CA IV were produced in Escherichia coli and mammalian cell cultures. Comparison of their temperature stability in various buffers and salt solutions demonstrated that CA IV is most stable at slightly alkaline conditions and at elevated sodium sulfate concentrations. High-resolution X-ray crystallographic structures of ortho-Cl and metathiazole-substituted benzene sulfonamide in complex with CA IV revealed the position of and interactions between the ligand and the protein. Sulfonamide inhibitor binding to CA IV is linked to several reactions-the deprotonation of the sulfonamide amino group, the protonation of malfunction of this metabolon correlates with some diseases (McMurtrie et al. 2004) . CA IV catalyses CO 2 exchange in lungs and the hydration of CO 2 that is produced in muscle during exercise . Together with CA XIV, CA IV is the main CA in the brain extracellular space that maintains pH homeostasis. CA XIV and CA IV also maintain intracellular pH in the hippocampal neurons (Svichar et al. 2009 ). Together with CA II, CA IV participates in compacting of myelin membranes, but CA IV alone is not sufficient to keep myelin compact (Cammer et al. 1995) . CA I-IV are found in esophageal epithelium where, among other functions, they protect against gastric acid reflux (Christie et al. 1997) .
CA IV plays a role in the development of several diseases, such as retinitis pigmentosa and glaucoma. Retinitis pigmentosa, an inherited progressive eye disease, results in blindness at the age of 40-50 years. Retinitis pigmentosa affects one in 3000-7000 people, both men and women (Köhn et al. 2008; Datta et al. 2009; Ferrari et al. 2011) . In these patients, CA IV carries the R14W mutation and the mutated protein cannot maintain the pH homeostasis, causing the photoreceptors to degenerate due to apoptosis (Yang et al. 2005) . Recently it was shown that CA IV plays a very important role in suppressing colorectal cancer and in wound healing (Zhang et al. 2016) . After injury, CA IV expression is induced by inflammation and, together with CA IX, it generates an acidic micro-environment, crucial for neutrophil survival and keratynocyte migration (Barker et al. 2017) . CA IV and CA III functions might be altered in rheumatoid arthritis, systemic lupus erythematosus, type 1 and 2 diabetic nephropathy, type 1 and 2 diabetes, and heart failure, since high titers of anti-CA III and/or anti-CA IV antibodies were found in the serum of people affected by these diseases (Liu et al. 2012 ). There are also antibodies to CA IV in the serum of people diagnosed with autoimmune pancreatitis and Sjögren's syndrome (Nishimori et al. 2005) .
CA IV is one of the most enzymatically active CA isoforms. Its k cat for CO 2 hydration is 1.1 × 10 6 s −1 while the CA II k cat is 8 × 10 5 s −1 . CA IV is also more active in HCO 3 − dehydration than CA II (Baird et al. 1997) . CA IV is inhibited by bromophenol compounds (Balaydin et al. 2012) . It is also inhibited by acetazolamide (AZM), ethoxzolamide (EZA), and bromosulfanilamide. Celecoxib and some halogenated sulfanilamides are also inhibitors of medium potency. CA IV is located outside the cell. Therefore, it can be selectively inhibited by positively charged sulfonamides that cannot cross the plasma membrane (Supuran 2008) . Since CA IV is involved in many processes, selective inhibitors might have clinical importance .
The crystal structure of the secretory form of human CA IV was first determined by Stams et al. (Stams et al. 1996) . A unique loop on the opposite side of the active site, the Val-131-Asp-136 segment, was found to be specific to this isozyme instead of the alpha-helix conformation found in other isozymes.
We have designed a series of 35 novel substituted benzenesulfonamides and have discovered a compound 19 (3-[(4-chloro-2-phenylsulfanyl-5-sulfamoyl-benzoyl)amino] propyl acetate) that bound CA IV with the K d of 1.0 nM and had significant selectivity towards this isoform over other human CA isoforms. The high-resolution crystal structure for compound 20 in complex with CA IV revealed the most important interactions between the ligand and protein.
A detailed thermodynamic analysis of EZA and trifluormethanesulfonamide (TFS) binding to CA IV was performed by isothermal titration calorimetry (ITC) and fluorescent thermal shift assay (FTSA) to determine the intrinsic thermodynamics of compound binding. Intrinsic values do not depend on pH or buffer because they take into account the binding-linked protonation reactions, while direct determinations of binding or inhibition by any enzymatic or biophysical techniques always yield the observed dissociation constants that should not be directly used to correlate the structure with thermodynamics. The pH dependence of the binding affinities and the observed enthalpies of binding enabled us to obtain the pK a and the enthalpy of protonation of the Zn bound water at the active site of CA IV. These values should help other researchers to determine the intrinsic thermodynamics of binding to CA IV and develop drugs targeting CA IV.
Results and discussion

Observed thermodynamics of ligand binding to CA IV
The binding affinity of a novel series of substituted benzenesulfonamides 1-35 ( Fig. 1) to CA IV was determined by FTSA. The compounds that bind to the active site of CA IV stabilized the protein and shifted the protein melting temperature (T m ) upward (Fig. 2) . The observed dissociation constants (K d-obs ) were obtained after the simulation or regression of the ligand-dosing curve according to the model (Cimmperman et al. 2008) . According to the data in Table 1 , many compounds showed better affinities for CA IV than the non-substituted compound benzenesulfonamide (BSA). Tetrafluorbenzenesulfonamide derivatives 1-10 bearing substitutions at the para position bound CA IV with K d-obs ranging from 50 to 830 nM. The introduction of ortho substituent (compounds 11-15) resulted in much weaker binding to CA IV (K d-obs in the range of 400-4000 nM). However, meta substituted derivatives 17-18 bearing a short hydroxyethylthio group at the para position had higher binding affinities (K d-obs 17-18 nM). For the series of 19-35 compounds, compound 19 was the most potent binder of CA IV, with an extraordinary K d-obs of 1 nM.
For analysis of the selectivity, we tested the binding of five selected compounds toward all CA isoforms and compared the data with BSA and AZM (Table 2) . Compound 5 was a selective and high-affinity binder of CA I and CA VB (K d-obs in the low nanomolar range), and had a lower affinity to CA IV and CA VA (K d-obs in the range 170-100 nM). Compounds 18, 19, and 26 bound CA IV 28, 4000, and 23-times stronger, respectively, than CA I, one of the most abundant isoforms found in the human organism. However, their binding affinity to CA VII, CA IX, CA XII, CA XIII, and CA XIV was higher or similar to CA IV. Compound 19 was selective toward CA IV, bound CA IV 4000 times stronger than CA I and 10 times stronger than CA II. This compound, or compounds with similar structures, may be developed as drugs targeting CA IV.
Crystal structure of CA IV in complex with inhibitors
The crystal structures of human CA IV in complex with the synthesized compound 20 and five commercially available CA inhibitors, namely EZA, AZM, methazolamide (MZM), 4-aminomethylbenzenesulfonamide chloride (PAMBS) and topiramate (TPM), were determined by X-ray crystallography. Data collection and refinement statistics are shown in Table 3 . The quality of electron densities for the complexes of compound 20 and five other inhibitors is shown in Fig. 3 , parts b1-b6. For the complex with compound 20, the asymmetric unit of the crystal structure contains four subunits. Three sets of electron densities attributable to the inhibitor were found in protein chains A, B, and C. The location of the compound is nearly identical in all three protein chains with small differences in the positions of the second ring.
The location of the 2-chlorobenzenesulfonamide ring in the active site of several human CA isoforms (CA XII, CA XIII, and CA II) described earlier (Čapkauskaitė et al. 2013 ) is very similar. The chlorine atom is anchored in a hydrophobic pocket formed by the residues conserved between human CA isoforms (in CA II Val121, Leu141, Val143, and Leu198). On the other hand, the active site of CA IV is more hydrophilic (Fig. 3c1 ), but the hydrophilic residues do not interact with inhibitor 20. The dissociation constants of compound 20 with CA IV and CA II are very similar (200 and 290 nM, respectively, Table 2 ). The dissociation constants of 20 with CA XII and CA XIII are also very similar (330 and 100 nM accordingly, Table 2 ). These values can reflect similar interaction of 20 with these CA isoforms (Fig. 3a1) , since a relatively simple compound interacts with the most conserved part of the CA binding site.
The buried surface area (in Å 2 ) calculated by PISA v1.06 (Krissinel and Henrick 2007) values of the side chains that interact with 20 for protein chain A are given in Table 4 . The largest buried surface area values contain residues Asn69, Met74, Gln96, His98, Leu207, and Thr209. Most of these residues are present both in CA IV and CA II isoforms, except for Phe131 in CA II, which does not have a structural counterpart in the crystal structures of CA IV, and Met74 in CA IV, which coincides spatially with Asn67 in CA II.
In the protein chain A of CA IV, an electron density was found, corresponding to residues Lys128-Gln140, that was absent in other protein chains of PDB ID 5IPZ as well as in other CA IV crystal structures (except PDB ID 1ZNC, 2.8 Å) (Stams and Christianson 2000; Vernier et al. 2010) . Despite the poor quality of the electron map, we were able to put most of the residues into the protein model. The flexible loop interacts with the surface of the symmetric equivalent of the protein chain B, and it is likely that such a conformation reflects an artifact of the crystal packing. Interestingly, the residues that correspond to this loop are quite well fixed in CAII (residues 127-137) (Fig. 3a2) Fig. 1 The structures of synthesized compounds 1-35 and six conventional CA inhibitors EZA, TFS, AZM, MZM, PAMBS, and TPM, that were used in this study active site in CA II. Phe131, which is often involved in the interaction with sulfonamide inhibitors, is also located in this region.
For the complexes with AZM, EZA, TPM, PAMBS, and MZM, crystals were grown in space group p2 1 2 1 2 1 , with almost identical unit cells containing four molecules in the asymmetric unit (Table 3 ). The structures of the CA molecules A, B, C, and D including inhibitors were very similar, with the rms deviation of ~0.2 Å for these five complexes. However, residues 126-138 (using the numbering of CA II) in molecules A and B were disordered while residues 126-138 in molecule C and D were ordered and visible in the electron density map. Comparing the structures of molecule C in the complex of CA IV and AZM, molecule A of PDB ID 1ZNC, the first crystal structure of human CA IV where the residues 126-138 in molecule B were disordered (Stams et al. 1996) , molecule A in complex of human CA IV and compound 20, and human CA II (PDB ID 4HT0) (Fig. 3a2) , showed that the orientation of residues 126-138 in CA IV differs greatly from CA II. The structure of residues 126-138 in CA II is very similar with that of another CA family, in which residue 131 was an important residue located in a short helix and interacted with inhibitors in most isoforms of the CA family. This helix acts as a lid and closes the active site pocket in CA II. The structures of residues 126-138 in human CA IV were very flexible and there were four different conformations (including the disordered one) in the segment found so far. Although the conformations in this region were different, all of them made the active site pocket bigger and allowed larger inhibitors to interact with the active site.
The active site structure in the complex of human CA IV and inhibitor consisted of a metal binding site, protein ligands from the nitrogen atoms of His94, His96, and His119 as well as the nitrogen atom from the inhibitor, a hydrophobic pocket containing the residues Val121,Val143, Ile141, Val207, Trp209, and Leu198, and a hydrophilic pocket consisting of Tyr7, Asn62, His64, Ser65, Met67, Gln92, Thr199, and Thr200. Figure 3 , parts c1, c2, c3, c4, c5, and c6, shows the interactions between inhibitors and the protein in the active site areas. All inhibitors formed two hydrogen bonds with the nitrogen atom from the main chain and the oxygen atom from the side chain of Thr199, which is a catalytic residue in CA IV. Residue His64 from the hydrophilic pocket is a proton shuttle in catalysis (Stams et al. 1996) . Gly-63-→ Gln substitution in rodent CA IV revealed the importance of residue His64 as a proton shuttle (Tamai et al. 1996) . In fact, the complex structure of CA IV and AZM in (Cimmperman et al. 2008) molecule A showed two conformations for the side chain of His64; one of them directed toward the active site and further certified the importance for this residue in CA IV. It was also observed that there were two conformations for the side chains of His64 in some crystal structures of CA II and CA VII. For the active site structure for compound 20 in complex with CA IV, there were no other interactions between the inhibitors and protein for the structures with EZA and PAMBS in CA IV (Fig. 3c3, c5 ), which revealed the most important hydrophobic interactions between the ligand and the protein. However, in the active site structure of CA IV with TPM, there were six hydrogen bonds in total between TPM and the hydrophilic residues. This bonding was attributed to the more hydrophilic oxygen atoms in TPM and provided a guide for designing new inhibitors with improved binding selectivity towards CA IV. Unfortunately, the crystal structure of 19 with CA IV was not obtained. This structure could have revealed the structural features of the lead compound, but the crystallization procedure was unsuccessful.
Determination of pK a of Zn-bound water molecule in the active site of CA IV
The pK a and enthalpy of protonation values of Zn(II)-bound hydroxide in CA cannot be determined directly by pH titration or ITC because there are many overlapping ionizing groups in proteins. Therefore, the pK a is determined indirectly by modeling the U-shape dependence of the affinity on pH and the X-shape observed enthalpy dependence on pH (Fig. 4) . The enthalpy of the hydroxide protonation is also determined from the model of the observed enthalpy dependence on pH in two buffers of different protonation enthalpy (Fig. 4) . The binding of EZA, measured by ITC in two buffers, phosphate (Pi) and TRIS, demonstrated the dependence of the observed binding enthalpy ∆ b H obs on the buffer (Fig. 4a) . The binding parameters strongly depended on the buffer pH as well, both for EZA and for TFS binding (Fig. 4b, c) . Fitting of the observed experimental data obtained in TRIS and Pi buffers by applying Eq. (4) yielded the intrinsic binding enthalpy (horizontal dashed line). Fitting of the data enabled the determination of the pK a of CA IV, which was equal to 7.0.
Another useful technique for the estimation of pK a of the Zn(II)-bound water form of CA IV is FTSA. Figure 4d shows the dependence of the observed binding affinity on pH. The resulting U-shape of pH dependence can be approximated by Eq. (1). The value of pK a for the Zn(II)-bound water form of CA IV used for fitting the U-shape was 6.5, a value which is slightly lower than that obtained by ITC technique. The intrinsic Gibbs energy for EZA binding was equal to −53.6 kJ/mol.
Characterization of CA IV stability by FTSA
FTSA was used to identify buffer conditions (pH ranges from 5 to 10) that stabilized CA IV. Different additives (salt Table 1 The tested compound affinities to CA IV, determined by the fluorescent thermal shift assay at pH 7.0 and 25 °C
The observed values were determined experimentally while the intrinsic affinities were calculated according to Eq. (1) Compound Compound lab name pK a K d_obs (nM) K d_intr (nM) substances, glycerol, DMSO) and EZA inhibitor concentrations were used to examine a stabilizing or destabilizing effect on CA IV. The stability of CA IV was affected by pH, buffer, and the presence of various salts (Fig. 5 ). The protein was most stable at pH 8.0-8.5 (Fig. 5a, b) . CA IV at pH 8.0 was more stable in Pi and HEPES buffers than in TRIS and carbonate buffers. Destabilization of CA IV by carbonate at pH 8-10 and by citrate buffer at pH 4.5-6.0 was observed. These buffers may have to be avoided in CA IV purification or storage. Regular salts such as sodium chloride, sodium sulfate, and ammonium sulfate had different influences on the stability of CA IV. Sodium sulfate exhibited the greatest stabilization effect on the protein-the addition of 1 M sulfate increased the protein T m by about 5 °C. Sodium chloride had a minor effect on CA IV stability, whereas the addition of ammonium sulfate slightly decreased protein T m , primarily because it diminished the pH of the protein solution (Fig. 5c) .
Both glycerol and DMSO had a minor destabilizing effect for CA IV (Fig. 5d) . At 5-10% (v/v) of glycerol, the protein stability decreased by about 1 °C. The addition of DMSO at these concentrations destabilized the protein by about 2 °C.
Intrinsic thermodynamics of ligand binding
In order to calculate the intrinsic binding parameters by Eq. (1), the protonation parameters of both protein and sulfonamide are necessary. The pK a s of most tested sulfonamides were previously determined Linkuviene et al. 2016 ). The pK a of the sulfonamide group for compound 19 was measured spectrophotometrically by measuring absorption at different pHs. The pK a s of 20, 27, and 32 were determined by analogy with other meta-and para-substituted benzenesulfonamides. We have recently shown that only the head-groups but not the tail groups on benzenesulfonamides influenced the ionization constants , thus the pK a for meta substituted compounds 20 and 27 with chlorine atoms were 8.9, and for para-substituted benzenesulfonamide 32 was 9.4. The thermodynamic parameters of protonation of the deprotonated inhibitor sulfonamide group and the CA-Zn(II)-bound hydroxide anion, determined by ITC at 25 °C, are listed in Table 5 .
The intrinsic K d-intr for synthesized compounds 1-35 and for reference compounds are listed in Table 1 . The intrinsic K d-intr for all compounds was significantly higher than the observed dissociation constants. It is evident that the lower the value of pK a for sulfonamide, the smaller the difference between the intrinsic and the observed dissociation constants (Fig. 6a, b) . The largest differences between the observed and intrinsic K d values were observed for compounds 34, 35, and BSA, where the binding to CA IV differed more than 8300-fold. The most tightly binding inhibitor, according to both the observed and intrinsic K d s, was compound 19, where the intrinsic K d reached 3.6 pM, whereas the observed K d was equal to 1.0 nM. Since the pK a of TFS was equal to 6.3, the lowest among the tested compounds, the intrinsic K d value for TFS was closest to the observed (
The enthalpy-entropy compensation graph (Fig. 6c ) shows that the intrinsic Gibbs energy of binding for the tested series of compounds (listed in Table 6 ) spreads over 24 kJ/mol, whereas the ΔΔ b H int varies by 38 kJ/mol and TΔΔ b S intr by 50 kJ/mol. There is no clear enthalpy-entropy compensation and the enthalpy and entropy contribution to binding affinity is favorable, except for AZM, for which the large negative enthalpy (Δ b H int = −50.6 kJ/mol) is slightly opposed by the negligible entropy contribution (TΔ b S intr = −3.7 kJ/mol). EZA, TPM, AZM, MTZ and compound 26 bound to CA IV with the dominant enthalpy contribution, whereas compounds 5, 18, 19 and 20-with the dominant favorable entropy. Favorable entropy and Table 2 The observed dissociation constants of selected compounds for all catalytically active human CA isoforms, determined by the fluorescent thermal shift assay at pH 7.0 and 25 °C The K d for compounds 5, 18, and 26 binding to CA I, II, VII, XII, and XIII are taken from our previously published data, recalculated to 25 °C (Dudutienė et al. 2013 (Dudutienė et al. , 2015 Čapkauskaitė et al. 2013; Zubrienė et al. 2017 The results presented here show that binding of CA IV to sulfonamides was significantly influenced by the composition of the buffer and its pH. The pK a and ionization enthalpy of the Zn(II)-bound water molecule in the active site of CA IV were determined due to the EZA and TFS titrations at various pHs of TRIS and Pi buffers. Measurement of the binding affinity at various pHs by FTSA helped validate the pK a values as well. When the pK a and the enthalpy of protonation of sulfonamide and protein, as well as the enthalpy of buffer protonation, are known, the intrinsic thermodynamic parameters can be calculated and correlated with the highresolution protein-ligand crystal structures. It was necessary to determine the pKa and enthalpy of protontion of the water molecule bound to Zn only once. When this has been accomplished here, future researchers can use these values in the calculation of the intrinsic parameters of any other sulfonamide ligand binding. A single determination at a single pH in a known buffer will be sufficient to calculate the intrinsic parameters. Such information may be valuable for further drug design of more effective and selective compounds. These known values enabled us to calculate the intrinsic binding values even from a single ITC titration experiment in a buffer with known protonation enthalpy and at a known pH (Table 6 ).
Conclusions
The observed binding affinity and the binding enthalpy of EZA to CA IV are pH-dependent. The pH dependence of the observed thermodynamic parameters shows the contributions of linked protonation-deprotonation reactions of both ligand and protein. The dissection of binding linked reactions yielded the intrinsic thermodynamic parameters, describing the reaction between the Zn-bound water form of CA IV and the anionic form of sulfonamide. The dominant intrinsic enthalpy contributed favorably to the Gibbs energy of EZA binding, whereas TFS binding was driven by entropy and enthalpy in equal parts. CA IV was most stable at pH 8.0-8.5. High sodium sulfate concentrations significantly stabilized the protein. Sodium chloride had insignificant effect on protein stability. High-resolution crystal structures for compound 20, EZA, and PAMBS in complex with CA IV revealed the most important hydrophobic interactions between the ligand and the protein. The structure of residues 126-138 in human CA IV was a loop conformation and was very flexible. There were four different conformations in the segment. Although the conformations in this segment were different, all of them made the active site pocket bigger and allowed larger inhibitors to interact with the active site. This conformation is a unique feature of CA IV in the CA family.
Experimental section Chemical compounds
EZA, AZM, TPM, MZM, TFS, and PAMBS were purchased from Sigma-Aldrich (St. Louis, MO, USA). The synthesis, chemical structural characterization, and the purity of compounds 1-35 has been previously described (Dudutienė et al. 2013 (Dudutienė et al. , 2015 Čapkauskaitė et al. 2013; Zubrienė et al. 2014) , with the exception of 19, 20, 27, and 32.
Synthesis of 19, 20, 27, and 32
All starting materials and reagents were commercial products and were used without further purification. The melting points of the synthesized compounds were determined in open capillaries on a Thermo Scientific 9100 Series apparatus without further correction. IR spectra were obtained on a Perkin-Elmer FT-IR spectrophotometer Spectrum BX II in KBr.
1 H and 13 C NMR spectra were recorded on a Varian Unity Inova (300 and 75 MHz, respectively) or Bruker C NMR spectra, respectively) as the internal standard. TLC was performed with silica gel 60 F254 aluminum plates (Merck, Kenilworth, NJ, USA) and visualized with UV light. High-resolution mass spectra (HRMS) were recorded on a Dual-ESI Q-TOF 6520 mass spectrometer (Agilent Technologies, Santa Clara, CA, USA). The purity of final compounds was verified by HPLC to be > 95% using the Agilent 1290 Infinity instrument with a Poroshell 120 SB-C18 (2.1 mm × 100 mm, 2.7 μm) reversed-phase column.
Analytes were eluted using a linear gradient of water/methanol (20 mM ammonium formate in both phases) from 60:40 to 30:70 over 12 min, then from 30:70 to 20:80 over 1 min, and then 20:80 over 5 min at a flow rate of 0.2 mL/min. UV detection was at 254 nm.
Compound 19a, 2,4-dichloro-5-sulfamoyl-benzoic acid, was converted to chloroanhydride, then subjected to amidation of the acid choride with 3-aminopropan-1-ol to produce the amide, compound 19b. Compound 19b was then treated to esterification with ethylacetate to produce compound 19c, 3-[(2,4-dichloro-5-sulfamoyl-benzoyl)amino] propyl acetate. Finally, compound 19c was converted to compound 19, 3-[(4-chloro-2-phenylsulfanyl-5-sulfamoylbenzoyl)amino]propyl acetate, via nucleophilic substitution of the choride with thiophenol (Scheme 1).
2,4-Dichloro-N-(3-hydroxypropyl)-5-sulfamoyl-benzamide (19b)
The mixture of 2,4-dichloro-5-sulfamoylbenzoic acid (19a) (2.70 g, 10.0 mmol), SOCl 2 (3.57 g, 30.0 mmol), and 1 drop DMF in toluene (5 ml) was refluxed for 4 h. Excess SOCl 2 and toluene were removed by distillation under reduced pressure, and the crude acid chloride was used directly in the next step. The solution of 2,4-dichloro-5-sulfamoylbenzoyl chloride in THF (30 ml) was added dropwise to a solution of 3-aminopropan-1-ol (2.25 g, 30.0 mmol) in THF (20 ml) at 0 °C and allowed to stirr for 1 h. The mixture was warmed to room temperature and stirred for another 2 h. THF was removed under reduced pressure. Water was added to the residue and product was extracted with EtOAc. 
3-[(2,4-Dichloro-5-sulfamoyl-benzoyl)amino]propyl acetate (19c)
2,4-Dichloro-N-(3-hydroxypropyl)-5-sulfamoyl-benzamide (19b) (327 mg, 1.00 mmol) was refluxed in EtOAc (7 mL) with 3 drops of concentrated H 2 SO 4 for 2 h. The reaction mixture was concentrated under reduced pressure and the resultant precipitate was washed with H 2 O. Yield: 288 mg, 78%, mp 149-151 °C.
1 H NMR (400 MHz) δ ppm: 1.83 (2H, quint, J = 6.4 Hz, CH 2 ), 2.02 (3H, s, CH 3 ), 3.30 (2H, q, J = 6.8 Hz, NHCH 2 ), 4.08 (2H, t, J = 6.4 Hz, CH 2 O), 7.81 (2H, s, SO 2 NH 2 ), 7.93 (1H, s, C 3 -H), 7.95 (1H, s, C 6 -H), 8.71 (1H, t, J = 5.6 Hz, NH).
13 C NMR (100 MHz) δ ppm: 21.2, 28.5, 36.5, 62.1, 129.1, 132.2, 132.5, 134.4, 136.1, 140.2, 164.9, 170.9 4, 130.8, 131.4, 132.3, 133.6, 135.2, 138.0, 144.6, 166. 5-(2-Aminothiazol-4-yl)-2-chloro-benzenesulfonamide (20) and 3-(4-chloro-3-methyl-phenyl)-5,6-dihydro-2H-imidazo[2,1-b]thiazol-3-ol (27) were obtained using the same reaction conditions from 5-(2-bromoacetyl)-2-chlorobenzenesulfonamide (20a) and thioureas (Scheme 2).
3-[(4-Chloro-2-phenylsulfanyl-5-sulfamoyl-benzoyl)amino] propyl acetate (19)
S -A l k yl a t i o n o f p h e nyl m e t h a n e t h i o l w i t h 5-(bromoacetyl)-2-chlorobenzenesulfonamide (32a) to give 4-(2-benzylsulfanylacetyl)benzenesulfonamide (32) was carried out in the presence of sodium acetate in tetrahydrofuran at room temperature (Scheme 3).
Synthesis of (20a) was accomplished from commercially available 1-(4-chloro-3-nitrophenyl)ethanone as reported previously (Oelschlager 1961) , Fujikura et al. 1982) . 4-(bromoacetyl)benzenesulfonamide (32a) was synthesized from commercially available 1-(4-aminophenyl)ethanone as described in (Fujikura et al. 1982) .
General procedure for the synthesis of 20, 27, and 32
A mixture of corresponding bromoacetophenone 20a, 32a (0.360 mmol), appropriate thioureas or phenylmethanethiol (0.704 mmol), and NaOAc (63.0 mg, 0.768 mmol) in THF (3 ml) was stirred at room temperature for 24 h. The reaction mixture was poured into water. The precipitate was filtered off, washed with water, and then with Et 2 O.
5-(2-Aminothiazol-4-yl)-2-chloro-benzenesulfonamide (20)
Yield 82%, mp 235-237 °C. IR ν cm −1 : 3444, 3353, 3257 (NH 2 ).
1 H NMR (300 MHz) δ, ppm: 7.20 (3H, s, NH 2 , C 5′ -H), 7.62 (2H, s, SO 2 NH 2 ), 7.63 (1H, d, J = 8.1 Hz, C 3 -H), 7.99 (1H, dd, J = 8.4 Hz, J = 2.1 Hz, C 4 -H), 8.46 (1H, d, J = 2.1 Hz, C 6 -H).
13 C NMR (75 MHz) δ, ppm: 104. 3, 126.8, 129.2, 130.2, 132.3, 134.7, 141.9, 148.2, 169.3 
3-(4-Chloro-3-methyl-phenyl)-5,6-dihydro-2H-imidazo[2,1-b]thiazol-3-ol (27)
Yield 80%, mp 158-160 °C.
1 H NMR (300 MHz) δ, ppm: 2.96-3.19 (2H, m, NCH 2 ), 3.69 (1H, d, J = 11.7 Hz, SCH 2 ), 3.79 (1H, d, J = 11.7 Hz, SCH 2 ), 3.91-4.12 (2H, m, NCH 2 ), 7.10 (1H, br s, OH), 7.69-7.72 (3H, m, C 3 -H, NH 2 ), 7.77 (1H, dd, J = 1.8 Hz, J = 8.1 Hz, C 4 -H), 8.20 (1H, d, J = 1.8 Hz, C 6 -H).
13
C NMR (75 MHz) δ, ppm: 42.9, 49.8, 61.4, 87.8, 127.5, 131.0, 131.8, 132.5, 141.7, 142.0, 170.4 13 C NMR δ, ppm: 35.9, 37.3, 126.6, 127.8, 129.2 (2C), 129.8, 130.0, 138.3, 148.5, 194.6 
Production of recombinant CA IV
The cDNA of CA IV was purchased from RZPD Deutsches Ressourcenzentrum für Genomforschung (Berlin, Germany). The gene encoding the catalytic domain of human CA IV (19-284 aa) was expressed in Escherichia coli Origami TM B (DE3) (Novagen, EMD Millipore, Billerica, MA, USA) cells. The transformed colony was transferred to BHI (Brain Heart Infusion) medium containing 60 μM ZnSO 4 and the cells were cultivated at 37 °C until reaching 0.6-0.7 OD 600 . Then 0.5 mM ZnSO 4 was added and protein expression was induced with 1 mM isopropyl β-d-1-thiogalactopyranoside (IPTG). The cells were grown for 20 h at 16 °C. The biomass was harvested by centrifugation at 4000×g for 20 min at 4 °C. Mammalian CA IV (19-284 aa) was produced as previously described (Dudutiene et al. 2014) .
The pellet was suspended in the lysis buffer (20 mM HEPES, 0.15 M NaCl, pH 8.0) containing 1× protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA) and 1 mM PMSF (SERVA, Heidelberg, Germany). The cells were incubated by mixing at 4 °C for 60 min and then sonicated for 15 min, 70% amplitude, using 1/1 min intervals. The supernatant was separated by centrifugation at 30,000×g for 25 min at 4 °C. Supernatant was mixed with p-aminomethylbenzene sulfonamide-agarose (SigmaLife Science Aldrich) and left to incubate overnight slightly shaken at 4 °C. The next day, CA IV (19-284 aa) was purified using a CA-affinity column containing the mentioned sorbent. Elution buffer contained 0.1 M sodium acetate, 0.5 M NaClO 4 , pH 5.6. Eluted protein was dialyzed into a buffer containing 20 mM HEPES, 20 mM NaCl, pH 8. After dialysis, CA IV (19-284 aa) was further purified using an anion exchange column with Q Sepharose TM Fast Flow (GE Healthcare, Little Chalfont, United Kingdom). Protein was eluted with 20 mM HEPES, 1 M NaCl, pH 8. Eluted protein was dialyzed into a storage buffer containing 20 mM HEPES, 50 mM NaCl, pH 7.5, and stored at −80 °C.
CA IV (19-284 aa) purity was confirmed using SDS-PAGE. Concentration was measured by the Bradford method. The molecular weight of the purified CA IV (19-284 aa) was measured by HRMS and was 30,320.74 Da, nearly equal to the theoretical molecular weight calculated from the amino acid sequence minus Met without water (30,323.4 Da). The difference in weight of 2 Da occurs due to the possible reduction-oxidation of Cys found in CA IV (19-284 aa).
Human CA IV was purified using CA-inhibitor affinity resins as described . Post affinity enzyme was dialyzed against 10 mM Tris-Sulfate pH 7.5 or 10 mM ammonium bicarbonate pH 8.0. Dialyzed enzyme was lyophilized for storage at 4 °C. Quality of the enzyme was assessed by SDS-PAGE and by measuring the specific activities. This CA IV preparation was used to obtain the crystal structures with AZM, MZM, PAMBS, EZA, and TPM. Both CA IV preparations gave specific activity of 3000-4000 EU/mg.
Compound binding to CA IV by isothermal titration calorimetry (ITC)
ITC measurements were performed using the iTC 200 instrument (Microcal, Inc., Northampton, MA, USA, now part of Malvern Instruments Ltd., UK). Protein solution (10 µM in the cell, volume 200 µl) was titrated with the compound solution in the syringe (100 µM, 40 µl). A typical experiment consisted of 19 injections, 2 µL each, with 2-3 min intervals between injections. Experiments were performed at 25 °C in 50 mM TRIS chloride or sodium phosphate buffers containing 100 mM NaCl and 0.5-2% DMSO concentrations both in the cell and syringe. Protein stock solutions were dialyzed against the buffers that were used to prepare the ligand solutions. ITC data were analyzed using MicroCal Origin software. The first point obtained using the 0.5 µL injection in the integrated data graph was deleted. The binding constants and the enthalpies and entropies of binding were estimated after fitting the data with the single binding site model.
The enthalpy of TPM deprotonation was measured using VP-ITC instrument. Inhibitor (0.25 mM) was deprotonated by adding 1.3 equivalent of NaOH and titrated with 2.5 mM HNO 3 . The experiment consisted of 58 injections (5 μl each) added at 4 min intervals. Experiment was performed at 25 °C with 0.5% of DMSO, equal in the syringe and the cell.
Compound binding to CA IV by the fluorescent thermal shift assay (FTSA)
During the FTSA experiments, the protein solution was heated from room temperature to 99 °C while following the extrinsic fluorescence of a solvatochromic probe, such as 1,8-anilinonaphthalene sulfonate (ANS), that strongly changes its fluorescence upon protein unfolding (Stryer 1965; Slavik et al. 1982; Matulis and Lovrien 1998; Matulis et al. 1999) . The thermal melting temperatures (T m ) are strongly dependent on the ligand binding affinity and concentration as previously described (Brandts and Lin 1990; Matulis et al. 2005; Cimmperman et al. 2008) . FTSA experiments were performed with a Corbett Rotor-Gene 6000 (QIAGEN Rotor-Gene Q) instrument using the blue channel (excitation 365 ± 20, detection 460 ± 15 nm), applying the heating rate of 1 °C/min. Usually the samples contained 20 µL of 10 µM protein, 0-400 µM ligand, 50 µM 8-anilino-1-naphthalene sulfonate, 50 mM sodium phosphate at pH 7.0, 50 mM NaCl, and 2% DMSO. The pH dependence of the observed binding constant (K b ) was determined in the buffer containing 50 mM sodium phosphate, 50 mM sodium acetate, 25 mM sodium borate, and 50 mM NaCl, pH 5.0-10.0. The FTSA data was fit and analyzed as previously described (Cimmperman et al. 2008) .
Intrinsic thermodynamics of compound binding to CA IV
Several linked reactions occur during sulfonamide inhibitor binding to CA that prevent direct determination of the intrinsic affinity, namely, the zinc-bound hydroxide ion protonation in the active center of the CA, the ligand sulfonamide group deprotonation, a coordination bond formation between the protein and deprotonated sulfonamide amine, and finally, the compensating protonation-deprotonation of the buffer.
Each of these reactions contributes to the observed binding parameters, the binding constant, and the enthalpy of binding.
The intrinsic binding constant K b_intr is equal to the observed binding constant K b_obs divided by the available fractions of deprotonated inhibitor and protonated Zn(II)-bound water form of CA The fractions of the deprotonated inhibitor and the Znbound water form of CA can be calculated if both pK a values of the sulfonamide (pK a_sulf ) and the CA (pK a_ZnH2O ) are known:
The observed enthalpy is the sum of all protonation events and the intrinsic binding reaction itself. Linked reactions that have to be subtracted are the protonation of the zinc-bound hydroxide ion in the active center of CA, deprotonation of sulfonamide, and the protonation/deprotonation of the buffer:
where ∆ b H obs is the observed binding enthalpy, n sulf = f RSO 2 NH − is the number of protons binding to the inhibitor, ∆ b_proton_sulf H is the enthalpy of inhibitor protonation, n CA = 1 − f CAZnH 2 O is the number of protons bound to the Zn-hydroxide, ∆ b_proton_CA H is the enthalpy of CA protonation, n buf = n sulf + n CA , is the net sum of taken up or released protons, and ∆ b_proton_buf H is the buffer protonation enthalpy. The enthalpy of TRIS protonation is equal to −47.45 kJ/mol and the enthalpy of phosphate buffer protonation is equal to −5.1 kJ/mol at 25 °C (Goldberg and Lennen 2002) .
Crystallization, X-ray diffraction data collection, and structure determination
The crystallization buffer contained 0.2 M ammonium sulfate, 0.1 M sodium MES (pH 6.5) and 20% PEG2000 methylmonoester, and crystals were obtained by crystallization of a mixture of CA IV (25 mg/ml) with 0.4 mM of compound 20 for the complex of CA IV and compound 20. For the other five complexes of CA IV and inhibitors, 8 mg/ml CA (1)
.
(2) f RSO 2 NH − = 10 pH−pK a_sulf 1 + 10 pH−pK a_sulf , 
Δ b H intr = Δ b H obs − n sulf Δ b_proton_sulf H − n CA Δ b_proton_CA H + n buf Δ b_proton_buf H, IV in 50 mM Tris sulfate, pH 8.0 and 2 mM benzamidine were mixed with 3-20 mM inhibitors (Table 1) before crystallization. Crystals were grown by the hanging drop vapor diffusion technique using an Art Robbins Instruments (Sunnyvale, CA, USA) Phoenix liquid handling robot in a solution of 100 mM Na acetate, pH 4.6, 200 mM ammonium sulfate, and 16-23% PEG 4000 or PEG 3350 (Table 1) . Crystals were grown in 1-2 weeks at 277 K and were cryoprotected in a solution containing mother liquid and 15% glycerol prior to flash freezing. Data were collected at the EMBL P14 beamline at the PETRAIII storage ring, DESY, Hamburg (Germany) for the complex with compound 20. Data for other complexes were collected with a home source (Rigaku 1.2 kw MMX007 generator with VHF optics) Rigaku Raxis IV ++ detector. All data were collected at 100 K. Datasets for the complex with compound 20 were processed by MOSFLM (Leslie 2006 ) and other datasets were indexed, integrated, and scaled with the HKL2000 software package (Otwinowski and Minor 1997) . All structures were solved by molecular replacement using the MOLREP program (Vagin and Teplyakov 1997) . The initial phases were received from PDB entry 3F7B for the complex with compound 20 and PDB entry 1ZNC for other complexes. For the complex with compound 20, 3D models of inhibitors were created using the molecule editor AVOGADRO (Hanwell et al. 2012) . The chemical and geometric descriptions of inhibitors used in refinement were generated by LIBCHECK CCP4 (Collaborative Computational Project, N. 4 1994) . For other complexes, the models of inhibitors were obtained from Protein Data Bank. A model of PAMBS was obtained from RCS (Triscarbonyl-cyclopentadienyl-4-aminomethylbenzene sulfonamide) and the Triscarbonyl-cyclopentadienyl was removed. The chemical and geometric descriptions for these inhibitors were generated automatically by REFMAC (Murshudov et al. 1997) . Refinement and electron density generation were performed with REFMAC (Murshudov et al. 1997) . Ten and 5% of the reflections were randomly selected as test sets for cross-validation for the complex with compound 20 and other complexes, respectively. Model building and analysis of the structures were carried out using COOT (Emsley and Cowtan 2004) . In the final refinement stage, TLS tensors modeling rigid-body anisotropic temperature factors were calculated and applied to the models except for the complexes with compound 20, EZA, and PAMBS. Ramachandran plots were calculated using PROCHECK (Morris et al. 1992) . Statistics for data collection and refinement are summarized in Table 3 . Atomic coordinates and structure factors have been deposited in Protein Data Bank (accession codes 5IPZ, 5JN8, 5JN9, 5JNA, 5JNC, and 5KU6 for the complexes with compound 20, AZM, EZA, TPM, PAMBS, and MZM, respectively).
PDB IDs: 5IPZ-20, 5JN8-AZM, 5JN9-EZA, 5JNA-TPM, 5JNC-PAMBS, and 5KU6-MZM. Authors will release the atomic coordinates and experimental data upon article publication.
